Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies
Molecules · 2023
DOI: 10.3390/molecules28217252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Heba E Hashem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Women, Ain Shams University, Cairo 11757, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyridazines, Nanoparticles. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University, Riyadh, Saudi Arabia through Researchers Supporting, King Saud University, Riyadh, Saudi Arabia through Researchers Supporting Project.
Abstract (Originalsprache)
The strategic planning of this study is based upon using the nanoformulation method to prepare nanoparticles 4-SLNs and 4-LPHNPs of the previously prepared 4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-amine (4) after confirming its structure with single crystal X-ray analysis. These nanoparticles exhibited promising cytotoxic activity against HepG-2, HCT-116 and MCF-7 cancer cell lines in comparison with the reference doxorubicin and the original derivative 4. Moreover, their inhibitory assessment against EGFR and CDK-2/cyclin A2 displayed improved and more favorable impact than the parent 4 and the references. Detection of their influence upon cancer biomarkers revealed upregulation of Bax, p53 and caspase-3 levels and downregulation of Bcl-2 levels. The docking simulation demonstrated that the presence of the pyrazolo[3,4-c]pyridazin-3-amine scaffold is amenable to enclosure and binding well within EGFR and CDK-2 receptors through different hydrophilic interactions. The pharmacokinetic and physicochemical properties of target 4 were also assessed with ADME investigation, and the outcome indicated good drug-like characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Women, Ain Shams University, Cairo 11757, Egypt.
- Applied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
- School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK.
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt.
- Department of Pharmaceutical Sciences, School of Pharmacy and Physician Assistant Studies, University of Saint Joseph, West Hartford, CT 06117, USA.
ORCID-Profile: Heba E Hashem, Abd El-Galil E Amr, Abdulrahman A Almehizia, Ahmed M Naglah, Benson M Kariuki, Heba A Eassa, Eman S Nossier
Förderung
- King Saud University, Riyadh, Saudi Arabia through Researchers Supporting
- King Saud University, Riyadh, Saudi Arabia through Researchers Supporting Project
Zitieren
APA
Hashem, H. E., Amr, A. E. E., Almehizia, A. A., Naglah, A. M., Kariuki, B. M., Eassa, H. A., & Nossier, E. S. (2023). Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies. Molecules. https://doi.org/10.3390/molecules28217252
Vancouver
Hashem HE, Amr AEE, Almehizia AA, Naglah AM, Kariuki BM, Eassa HA, et al. Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies. Molecules. 2023. doi:10.3390/molecules28217252
BibTeX
@article{Hashem2023,
author = {Hashem, Heba E and Amr, Abd El-Galil E and Almehizia, Abdulrahman A and Naglah, Ahmed M and Kariuki, Benson M and Eassa, Heba A and Nossier, Eman S},
title = {Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28217252}
}
EUVIMED